{"id":"gprc5d","name":"GPRC5D","symbol":"GPRC5D","route":"/targets/gprc5d/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13310","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111291","uniprot":"https://www.uniprot.org/uniprotkb/Q9NZD1/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9NZD1","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4523925","open-targets":"https://platform.opentargets.org/target/ENSG00000111291","civic":"https://civicdb.org/genes/55507/summary","oncokb":"https://www.oncokb.org/gene/GPRC5D","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPRC5D","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=GPRC5D","depmap":"https://depmap.org/portal/gene/GPRC5D?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000111291-GPRC5D","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/55507","omim":"https://www.omim.org/entry/607437"}],"products":[{"id":"arlocabtagene-autoleucel","name":"Arlocabtagene Autoleucel","status":"phase-3","modality":"CAR-T cell therapy","route":"/drugs/arlocabtagene-autoleucel/"},{"id":"talquetamab","name":"Talquetamab","status":"approved","modality":"Bispecific T-cell engager (GPRC5D×CD3)","route":"/drugs/talquetamab/"}],"trials":[{"id":"nct05455320","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","nct":"NCT05455320","phase":"3","status":"active"},{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"quintessential-2","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","nct":"NCT06615479","phase":"3","status":"recruiting"},{"id":"nct06550895","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","nct":"NCT06550895","phase":"2","status":"active"},{"id":"nct06577025","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","nct":"NCT06577025","phase":"2","status":"active"},{"id":"nct06500884","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","nct":"NCT06500884","phase":"2","status":"recruiting"},{"id":"nct06297226","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT06297226","phase":"2","status":"recruiting"},{"id":"monumental-1","name":"MonumenTAL-1","nct":"NCT04634552","phase":"1/2","status":"positive"},{"id":"nct04586426","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT04586426","phase":"1/2","status":"active"}],"pathways":[],"companies":["bms","johnson-johnson"],"keyPapers":["paper-magnetismm-3-elranatamab-natmed-2023"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"bcma-directed","mechanism":"BCMA antigen loss (biallelic TNFRSF17 deletion, extracellular mutations)","category":"antigen"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}